Although the Brazilian Ministry of Health considers that anti-EGFR TKI is a therapeutic option in cases of advanced lung cancer with the presence of EGFR mutation, the reimbursement offered by the Ministry of Health is insufficient for targeted therapy to be used. Here, EGFR is linked to lung carcinoma.